BESTATIN TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND THE EFFECTS OF BESTATIN ON HEMATOPOIESIS IN MDS

被引：6
作者：
UZUKA, Y
SAITO, Y
机构：
[1] Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai
来源：
ACTA ONCOLOGICA | 1990年 / 29卷 / 06期
关键词：
Bestatin; Hematopoietic stem cells; Myelodysplastic syndromes;
D O I：
10.3109/02841869009093004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A high remission rate (75% was achieved in a preliminary study using bestatin in patients with refractory anemia with excess blasts (RAEB) and RAEB in transformation (RAEB-t). One of 2 patients with RAEB-t and 3 of 6 patients with RAEB obtained complete response. Two patients with RAEB achieved good response, but one with refractory anemia failed. Clonogenic marrow cell culture studies in patients with myelodysplastic syndromes have demonstrated intrinsic hematopoietic stem cell abnormalities, in particular defective erythroid colony formation. After bestatin treatment, these abnormalities as well as hematologic findings were markedly improved. The results suggest that bestatin has an enhancing effect on burst promoting activity production of helper (CD4 positive) T lymphocytes and the effect on hematopoiesis of bestatin may be mediated by T lymphocytes. ©1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码：803 / 807
页数：5
相关论文
共 11 条
[1]   PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199
[2]   A AND B BLOOD-GROUP ANTIGEN EXPRESSION ON MIXED COLONY CELLS AND ERYTHROID PRECURSORS - RELEVANCE FOR HUMAN ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
BLACKLOCK, HA ;
KATZ, F ;
MICHALEVICZ, R ;
HAZLEHURST, GRP ;
DAVIES, L ;
PRENTICE, HG ;
HOFFBRAND, AV .
BRITISH JOURNAL OF HAEMATOLOGY, 1984, 58 (02) :267-276
[3]  
COIFFIER B, 1983, CANCER, V52, P83, DOI 10.1002/1097-0142(19830701)52:1<83::AID-CNCR2820520117>3.0.CO
[4]  
2-9
[5]  
FAUSER AA, 1978, BLOOD, V52, P1243
[6]  
FOUCAR K, 1985, CANCER, V56, P553, DOI 10.1002/1097-0142(19850801)56:3<553::AID-CNCR2820560323>3.0.CO
[7]  
2-Q
[8]   THE MYELODYSPLASTIC SYNDROME - ANALYSIS OF LABORATORY CHARACTERISTICS IN RELATION TO THE FAB CLASSIFICATION [J].
MAY, SJ ;
SMITH, SA ;
JACOBS, A ;
WILLIAMS, A ;
BAILEYWOOD, R .
BRITISH JOURNAL OF HAEMATOLOGY, 1985, 59 (02) :311-319
[9]   BESTATIN, AN INHIBITOR OF AMINOPEPTIDASE-B, PRODUCED BY ACTINOMYCETES [J].
UMEZAWA, H ;
AOYAGI, T ;
SUDA, H ;
HAMADA, M ;
TAKEUCHI, T .
JOURNAL OF ANTIBIOTICS, 1976, 29 (01) :97-99
[10]  
WISNIEWSKI D, 1985, BLOOD, V65, P456
12